|Bid||186.53 x 900|
|Ask||187.75 x 900|
|Day's range||184.74 - 187.51|
|52-week range||163.31 - 201.23|
|PE ratio (TTM)||61.11|
|Earnings date||23 Jul 2018 - 27 Jul 2018|
|Forward dividend & yield||5.28 (2.85%)|
|1y target est||195.30|
Jun.18 -- President Donald Trump is threatening to slap tariffs on another $200 billion in Chinese imports as trade tensions between the world’s two largest economies reach new heights. William Zarit, chairman of the American Chamber of Commerce in China, weighs in on "Bloomberg Daybreak: Asia" with Yvonne Man.
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
The size of Amgen Inc (NASDAQ:AMGN), a US$122.46B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More...
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.
Alder Biopharmaceuticals likely will seek a buyer, an analyst said Thursday as shares tanked on the hire of a new chief executive.
Being first to market helps Mylan, as does the competitive landscape for Neulasta biosimilarsBloomberg NewsHeather Bresch, chief executive officer of Mylan, speaks during an interview in New York in 2016. Mylan NV marked a major success late Monday with the first U.S. approval of a biosimilar version of Neulasta, an anti-infective used for patients undergoing cancer treatment. Biosimilar drugs are copycat versions of expensive biologic drugs, which treat complex diseases like cancer, multiple sclerosis and diabetes.
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Mylan spiked to a nearly eight-week high Tuesday after the FDA approved its copycat drug to Amgen's blockbuster medication Neulasta, a treatment that is used to stimulate bone marrow.
Alexion Pharmaceuticals will likely keep 75% of its Soliris market in the U.S. even as rivals like Amgen try to copy the blockbuster drug, an analyst said Tuesday in a bullish note.
The S&P 500 edged slightly higher on Tuesday, on track for its third straight day of gains, while Nasdaq hit an intraday record high with help from the technology and consumer discretionary sectors. Amazon.com ...
U.S. shares of Mylan NV rallied in the extended session after the drug maker received Food and Drug Administration approval for a biologic drug that is similar to one made by Amgen Inc. . Mylan ADRs surged ...
Amgen and Allergan were sidelined Friday after the FDA delayed their Herceptin biosimilar, giving Roche's blockbuster breast cancer drug some breathing room.
With (Other OTC: WWTH - news) women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The injectable monoclonal antibody that Novartis has developed with Amgen (NasdaqGS: AMGN - news) won approval in the United States this month and on Friday bagged a recommendation from a key European panel, clearing the way for likely approval on the continent. Novartis is also considering new pricing models for Aimovig.
Novartis's (NOVN.S) generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's (ABBV.N) Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for marketing authorisation of Novartis's proposed biosimilar adalimumab. The European Commission nearly always follows the CHMP recommendation.
GlaxoSmithKline’s (GSK) Vaccines segment includes various vaccines, including meningitis vaccines, influenza vaccines, shingles vaccines, and established vaccines. GlaxoSmithKline acquired meningitis vaccines from Novartis (NVS) in 2016.